IPO - Genprex, Inc.

Form Type: S-1

Filing Date: 2025-05-14

Corporate Action: Ipo

Type: New

Accession Number: 000143774925016611

Filing Summary: Genprex, Inc. is filing a registration statement for an Initial Public Offering (IPO) of up to 27,586,206 shares of common stock and accompanying warrants to the public. The offering includes common stock and prefunded warrants with specified exercise prices and conditions for purchase. The company is utilizing its ONCOPREX® Delivery System for gene therapy focused on oncology, including its lead candidate REQORSA® targeting Non-Small Cell and Small Cell Lung Cancer, and also has a diabetes treatment platform. The public offering is expected to commence as soon as practicable after the registration statement becomes effective, with an offering termination date set for June 30, 2025. Genprex is classified as a smaller reporting company and is currently listed on The Nasdaq Capital Market under the symbol "GNPX." The offering's structure includes placement agent fees and highlighted risks related to market conditions, ability to raise funds, and regulatory approvals as critical points of concern for investors.

Form Type: DRS

Filing Date: 2025-04-24

Corporate Action: Ipo

Type: New

Accession Number: 000143774925012862

Filing Summary: Genprex, Inc. filed a registration statement with the SEC under Form S-1 to register securities for an upcoming public offering. The document details the offering of up to shares of common stock, pre-funded warrants, and accompanying warrants, highlighting the company’s gene therapy developments aimed at unmet medical needs in oncology and diabetes. The prospectus specifies that the common stock will be listed on The Nasdaq Capital Market under the symbol 'GNPX', and outlines the potential risks and strategies associated with the offering. The effective date of this offering is contingent upon SEC approval and market conditions, with Genprex planning a comprehensive execution of their clinical trials while noting that any funds raised will be utilized immediately for business operations, despite potential uncertainties in fulfillment of business goals. Key points also mention collaboration with MD Anderson Cancer Center for biomarker discovery and the dual functionality of their lead candidate REQORSA within existing treatments for lung cancer.